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Summary: Endometrial cancer is the most common gynecologic neoplasm in developed
countries; however, updated universal guidelines are currently not available to handle
specimens obtained during the surgical treatment of patients affected by this disease. This
article presents recommendations on how to gross and submit sections for microscopic
examination of hysterectomy specimens and other tissues removed during the surgical
management of endometrial cancer such as salpingo-oophorectomy, omentectomy, and
lymph node dissection—including sentinel lymph nodes. In addition, the intraoperative
assessment of some of these specimens is addressed. These recommendations are based
on a review of the literature, grossing manuals from various institutions, and a
collaborative effort by a subgroup of the Endometrial Cancer Task Force of the
International Society of Gynecological Pathologists. The aim of these recommendations
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is to standardize the processing of endometrial cancer specimens which is vital
for adequate pathological reporting and will ultimately improve our understanding of
this disease. Key Words: Endometrial carcinoma—Gross examination—Macroscopic
examination—Processing—Pathology—Tumor size—Staging—Lymph nodes—Sentinel
lymph nodes.
Endometrial cancer is the sixth most common
malignant neoplasm in women worldwide and is the
most common gynecologic malignancy in developed
countries (1). In the United States, the American
Cancer Society estimates ∼63,230 new cases of
endometrial cancer and 11,350 deaths due to this
disease in 2018 (2). Although no updated universal
guidelines are currently available on how to gross the
surgical specimens obtained in cases of endometrial
cancer, it is widely accepted that a thorough gross/
macroscopic examination will optimize the acquisition
of information required for proper diagnosis, staging,
treatment, and prognosis. This article presents the
recommendations to handle and gross such specimens
as proposed by the members of the Endometrial Cancer
Task Force of the International Society of Gyneco-
logical Pathologists. These recommendations cover not
only hysterectomy specimens, including those obtained
prophylactically in patients at risk of developing this
disease, but also salpingo-oophorectomy and omentec-
tomy specimens, as well as sentinel and non–sentinel
lymph nodes (SLN). This work is based on a review of
the literature, grossing manuals from various institu-
tions, and a collaborative effort by a subgroup of the
above-mentioned task force. These recommendations
will assist in standardizing the processing of these
specimens, which is critical not only for an accurate
pathology report, but also to improve our knowledge of
this disease.
RECOMMENDATIONS
General
All pathology reports should include a detailed section
code/block key on which the origin/designation of all
tissue blocks should be recorded. This information is
particularly important should there be a need for internal
or external review as reviewers need to be clear about the
origin of each tissue block in order to provide an
informed specialist opinion. Recording the origin/desig-
nation of all tissue blocks also facilitates retrieval of
blocks for immunohistochemical or molecular analysis,
research studies or clinical trials.
HYSTERECTOMY SPECIMEN HANDLING
General Rule of Gross/Macroscopic Examination
Orient the specimen, that is identify the anterior and
posterior walls of the uterus using anatomic landmarks
FIG. 1. Orientation of hysterectomy specimen using anatomical landmarks, peritoneal reflection is higher anteriorly (arrow) and the sequence
of structures in the adnexal region is round ligament (*), fallopian tube (arrowhead) and ovary (**) (A), peritoneal reflection is lower posteriorly
(arrow) and the sequence of structures in the adnexal region is ovary (**), fallopian tube (arrowhead) and round ligament (B), the latter is not
visualized in this photograph.
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such as the peritoneal reﬂection and the round ligament/
ovaries (Figs. 1A, B). Document all organs/structures
received and record their measurements and gross
appearance.
WHEN SHOULD THE UTERUS BE OPENED?
Recommendation
Uteri should be opened immediately upon receipt in
the pathology laboratory and placed in formalin
within an hour of opening whenever possible.
The purpose of opening the uterus immediately is to
prevent autolysis, which is very common in hysterec-
tomy specimens, and to avoid potential preanalytical
issues when ordering immunohistochemical or molec-
ular studies (3–5). Although most of the grossing
manuals used in academic institutions in North
America do not provide speciﬁc timelines, some include
speciﬁc instructions such as opening and ﬁxation within
1 h of receipt in the pathology laboratory, documenta-
tion of cold ischemic interval and interval in formalin,
and prompt procurement of fresh tissue for banking
and/or investigational protocol purposes (6).
SHOULD THE PATHOLOGY PERSONNEL
MANAGE REQUESTS FOR FRESH TISSUE
FOR STUDIES?
Recommendation
The pathology laboratory personnel and/or pathol-
ogists should manage the requests for fresh tissue for
banking and/or investigational protocols and this task
should be completed as soon as the specimen is
received in the pathology laboratory.
Procurement of fresh tissue for banking or research
protocols should be done as soon as possible as prolonged
ischemia affects tissue quality for investigational purposes.
Tissue procurement for research should not compromise
pathologic evaluation (6–10). Therefore, a pathologist
should be consulted in questionable cases. In addition, the
tissue procured for research should be available for
diagnostic purposes if needed.
SHOULD THE PERITONEAL AND/OR NON-
PERITONEAL SURFACES BE INKED?
Recommendation
Inking of peritoneal and/or nonperitoneal surfaces
is recommended in hysterectomy specimens and is
mandatory in radical hysterectomy specimens in
which parametrium and vaginal cuff are present.
Serosal inking can aid in specimen orientation and in
conﬁrming the presence of tumor at the uterine serosal
surface if present (Figs. 2A, B). In addition, inking the
peritoneal and nonperitoneal surfaces and extending the
ink all the way to the ectocervical/vaginal cuff margin in
cases where the tumor has invaded the cervical stroma is
useful to provide an accurate measurement of the depth
of cervical stromal invasion relative to the full thickness
of the cervical wall and the status of the ectocervical/
vaginal cuff margin (Figs. 2C, D). Of note, measurement
of the depth of cervical stromal invasion and its
relationship with the full thickness of the cervical wall
are not included in the College of American Pathologists
(CAP) protocol for endometrial cancer (11), but they are
often required by radiation oncologists to delineate
treatment recommendations (12). The practice of
inking is variably addressed in the multiple grossing
manuals reviewed. Some manuals do not mention it at
all while others recommend inking as follows: (1)
serosal/nonserosal surfaces for orientation purposes, (2)
inking serosal abnormalities only to conﬁrm tumor at
the serosal surface, and (3) inking only of the
parametrium and vaginal cuff if present. Overall,
inking is helpful, but it is important to blot the inked
surfaces right after applying the ink to avoid ink
displacement and the potential misinterpretation of
this ﬁnding.
SHOULD THE UTERINE WEIGHT BE
INCLUDED IN THE REPORT?
Recommendation
The need to include the uterine weight in the
pathology report is geographically dependent. This
parameter has to be provided in the United States
because the Current Procedural Terminology (CPT)
code required for reimbursement purposes changes
according to a uterine weight of 250 g (i.e. CPT code
58570 is used for a uterus with a weight of ≤ 250 g
while CPT code 58572 is used for the same specimen if
the uterus weighs > 250 g) (13–15).
Although uterine weight could be related to surgical
outcome as larger uteri may be associated with increased
duration of surgery or risks of surgical complications
(16–18), the main reason to include uterine weight in the
pathology report is to ensure proper reimbursement for
the procedure when this is performed in the United
States. In addition, this information is also required for
the case list submitted by candidates applying to
certiﬁcation by the American Board of Obstetrics and
Gynecology in the United States (19).
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HOW SHOULD THE UTERUS BE OPENED?
Recommendation
The uterus should be opened along the lateral
uterine walls (3 and 9 o’clock).
The above method provides maximum exposure of the
endometrial surface in a ﬂat plane which allows better
visualization and measurement of the tumor (Fig. 3A).
Of note, the lateral uterine walls contain the cornua and
the pathologist should be aware that tumor involving the
lumen of the proximal portion of the fallopian tube can
be interpreted as myoinvasive carcinoma (Figs. 3B, C).
All grossing manuals examined for this review, in which
this procedure is described, recommend opening the
uterus along the lateral walls (6).
SHOULD THE TUMOR ALWAYS BE
MEASURED IN 3 DIMENSIONS?
Recommendation
At least the largest dimension of the tumor must be
provided, although providing 3 dimensions of a
neoplasm is often considered “best practice” and
represents standard pathology practice.
Currently, there is some controversy with regards to the
impact of tumor size on patient outcome; nevertheless,
tumors exceeding various established thresholds have been
associated with increased stage of disease and/or risk of
recurrence (20–27). Therefore, at a minimum, the largest
dimension of the tumor should be reported (Figs. 4A, B).
The other dimensions can be recorded, but are not
required. Some manuals specify the need to record the 3
dimensions of a tumor; however, this is not a uniform
approach as requirements for measurements are
not speciﬁcally outlined in several of the manuals
reviewed while others require 2 or only 1 tumor
dimension (6). The Royal College of Pathologists
Dataset for Histopathological Reporting of Endometrial
Cancer in the United Kingdom (28) recommends only
recording the maximum tumor dimension while the
current CAP checklist includes only the maximum
tumor dimension as an optional element which is not
required for accreditation (11). Another important
issue regarding tumor size is that this parameter has a
FIG. 2. Inking the anterior and posterior uterine serosal surfaces with extension of the ink to the ectocervix or vaginal cuff margin (A), helps to
confirm the presence of tumor in the uterine serosa (arrow) (B), and in cases with cervical stromal involvement (C) the measurement of the
relationship of the stromal invasion to the full thickness of the cervical wall (line), and the proper identification of the ectocervical or vaginal
cuff margin (*) (D).
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pivotal role in one of the algorithms used to triage
patients intraoperatively for lymph node dissection in
the setting of low-risk endometrial carcinoma. The
so-called “Mayo algorithm” is based on an association
between tumor size and risk of lymph node meta-
stases (21,22). According to this algorithm, patients
with endometrioid adenocarcinoma, FIGO grades 1 or 2,
measuring ≤2 cm and with ≤50% myometrial invasion
are spared of pelvic lymph node dissection as the risk of
lymph node metastases is <0.3% while patients with
similar tumors measuring >2 cm and ≤50% myometrial
invasion undergo a dissection of pelvic lymph nodes as
the risk of pelvic lymph node metastases increases to
10% (21).
The controversy between tumor size and disease
outcome can be summarized as follows: (1) some
studies have shown an association between tumor size
and risk of lymph node metastases, but tumor size has
not been found to be an independent predictive factor
when depth of myometrial invasion and lymphovas-
cular invasion are included in multivariate analysis
(23,24); (2) some studies have demonstrated an
association between tumor size, either ≥ 3.5 or > 5
cm, and recurrence risk and/or prognosis in otherwise
low-risk cancers (25,26); (3) other studies have not
shown an association between tumor size and prognosis
(24,27).
HOW SHOULD THE UTERUS BE SECTIONED
(HORIZONTAL/TRANSVERSE
OR LONGITUDINALLY)?
Recommendation
Horizontal/transverse sectioning is recommended.
All manuals reviewed, except one, suggest the use of
horizontal/transverse sectioning (left to right) from the
lower uterine segment to the fundus. However, vertical
sectioning is advisable to demonstrate the lower uterine
segment in conjunction with upper cervix (6) (Fig. 5).
FIG. 3. Opening the uterus at 3 and 9 o’clock provides a maximum exposure of the endometrial surface in a flat plane to better visualize and
measure an endometrial tumor (A), the cornua can contain tumor (B) and this should not be mistaken for myometrial invasion (C).
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SHOULD THE TUMOR BE SUBMITTED
ENTIRELY FOR HISTOLOGIC EXAMINATION?
IF NOT, HOW SHOULD THE NUMBER OF
SECTIONS BE DETERMINED?
Recommendation
It is not necessary to submit an endometrial tumor
in its entirety for microscopic examination. Sampling
one section per centimeter of the largest tumor dimension
(as is done with tumors at other anatomic sites) will
sufﬁce.
Grossing manuals provide a wide range of recom-
mendations; however, none advocates submitting the
entire tumor unless it measures ≤ 3 cm. Several
manuals advocate one section per centimeter of largest
tumor dimension (6). Also, a proposal for submitting at
least 4 blocks of tumor has been presented (28). Of note,
there are no data explicitly addressing the value of
extensive histologic examination of an endometrial
carcinoma. Although the risk of missing a high-grade
(serous, clear cell, undifferentiated or neuroendocrine)
carcinoma component in association with an endome-
trioid carcinoma exists, these cases are uncommon (29).
HOW MANY SECTIONS DO YOU TAKE IF
YOU DO NOT SEE CARCINOMA ON GROSS
EXAMINATION, IF THERE IS A HISTORY OF
ATYPICAL ENDOMETRIAL HYPERPLASIA/
ENDOMETRIOID INTRAEPITHELIAL
NEOPLASIA (EIN) OR IF UNSUSPECTED
ATYPICAL ENDOMETRIAL HYPERPLASIA/
EIN OR ENDOMETRIAL CARCINOMA IS
DETECTED IN THE REPRESENTATIVE
SECTIONS OF A HYSTERECTOMY OBTAINED
FOR OTHER REASONS?
Recommendation
The entire endometrium and adjacent inner my-
ometrium should be submitted for microscopic
examination in the setting of a preoperative endome-
trial sampling demonstrating malignancy and no
visible lesion on gross examination or if there is a
history of atypical endometrial hyperplasia/EIN. The
same applies to hysterectomy specimens that have
been obtained for other reasons (leiomyomas, adeno-
myosis, etc.) with no gross endometrial lesion and
endometrial carcinoma or atypical endometrial hyper-
plasia EIN detected on microscopic examination of
FIG. 4. Measurement of endometrial carcinoma, small polypoid tumor (A), a tumor that involves the anterior and posterior walls in a
continuum, carpet-like fashion should be measured accordingly (B).
FIG. 5. Cross-sections of the uterine wall at the level of the corpus
(top arrow), longitudinal sections at the level of the lower uterine
segment (middle arrow) and cervix (bottom arrow).
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the initial representative sections. Sections of residual
myometrium should be placed in sequential order,
either in folded paper towels or gauze, in a formalin
ﬁlled container in case that the examination of
additional myometrial tissue is needed to determine
an accurate depth of myometrial invasion if any.
In addition, cornual blocks need to be submitted in
cases of biopsy proven carcinoma, but no gross
endometrial tumor.
Most reviewed manuals recommend submitting the
entire endometrium when a preoperative diagnosis of
malignancy has been rendered and no gross lesion is
seen in the hysterectomy, or in cases of atypical
endometrial hyperplasia/EIN (6). In addition, the
Royal College of Pathologists of the United Kingdom
recommends the submission of cornual blocks in cases
of biopsy proven carcinoma, but no visible endome-
trial tumor on gross examination (28). Of interest, the
intraoperative evaluation of 1 random full thickness
section of the uterine wall from hysterectomies
obtained for endometrial carcinoma and no gross
lesion demonstrated the presence of microscopic
tumor only in 3 (15%) of 20 cases with a ﬁnal
diagnosis of cancer (30).
HOW MANY SECTIONS SHOULD INCLUDE
THE FULL THICKNESS OF THE MYOME-
TRIUM TO DETERMINE THE MAXIMUM
DEPTH OF INVASION?
Recommendation
At least, one full thickness section of the uterine
wall—including serosa, is required to show the
deepest point of myometrial invasion. In uteri with
a relatively thin wall which allows the submission
of a full thickness section in a single cassette, it is
possible to submit all sections containing tumor as
full thickness sections.
The manuals reviewed offered a wide range of
recommendations, from at least one full thickness
section to all submitted sections containing tumor to
be of full thickness (6,28). In ideal circumstances, a
single full thickness section submitted after a careful
gross examination would be sufﬁcient to determine the
deepest point of myometrial invasion (Fig. 6). However,
myometrial invasion assessment may be complicated in
certain circumstances such as cases with adenomyosis
involved by carcinoma, cases with peculiar patterns of
myometrial invasion like “adenoma malignum-like,”
“single cells,” “microcystic, elongated, and fragmented”
(31) or if an underlying leiomyoma is present distorting
the uterine wall architecture. It should be noted that the
examination of the myometrium is important not only
for assessment of depth of tumor invasion, but also to
identify the unusual inﬁltrative patterns mentioned
above and to identify and quantify lymphovascular
invasion. Regarding the assessment of the deepest
myometrial invasion in frozen section, several studies
have examined this issue and the number of sections
used has ranged from 1 to 5 (32–37). Depth of
myometrial invasion is an independent predictor of
both lymph node metastases and prognosis (38) and
is part of the FIGO staging system (39). In cases
where the gross examination does not allow the
submission of the deepest point of invasion with
conﬁdence or in problematic cases such as those
above, processing several full thickness sections of
the uterine wall may be necessary in order to render
an accurate assessment.
IF ADENOMYOSIS IS SUSPECTED, HOW
MANY SECTIONS SHOULD SAMPLE THE
FULL THICKNESS OF THE MYOMETRIUM TO
DETERMINE THE MAXIMUM DEPTH OF
INVASION?
Recommendation
The number of sections submitted should not be
altered in the context of adenomyosis. However, in
cases where the assessment of myometrial invasion is
difﬁcult because of tumor involving adenomyosis
taking additional sections of the uterine wall may be
useful.
None of the manuals reviewed addresses the
measurement of myometrial invasion in the context
of adenomyosis (6).
FIG. 6. Cross-section of the uterine wall demonstrating deepest
point of myometrial invasion on gross examination (arrowhead).
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SHOULD THE TUMOR/NONTUMOR INTER-
FACE BE SAMPLED?
Recommendation
Whenever possible, the tumor/nontumor interface
should be submitted for microscopic examination.
This facilitates the measurement of the depth of
myometrial invasion and the identiﬁcation of pre-
cursor lesions.
Some of the manuals reviewed speciﬁcally indicate
the need to sample the tumor/nontumor interface (6).
HOW MUCH NON-NEOPLASTIC ENDOME-
TRIUM SHOULD BE SUBMITTED?
Recommendation
At least one representative section of non-neoplastic
endometrium should be submitted for microscopic
examination. In addition, any grossly identiﬁed endome-
trial lesions separate from the tumor should be submitted.
There is no universal recommendation about the
number of sections of grossly unremarkable endome-
trium to be submitted. Some manuals recommend
submitting one or 2 full thickness sections of uninvolved
endomyometrium (6).
HOW MANY SECTIONS OF ENDOMETRIUM
AND ADNEXAL STRUCTURES SHOULD BE
TAKEN IF THE PATIENT IS KNOWN TO HAVE
LYNCH SYNDROME?
Recommendation
All gross endometrial abnormalities need to be
submitted for microscopic examination. In the absence
of a gross lesion, the endometrium should be submitted
in toto. Macroscopic examination and sampling should
be performed after ﬁxation, in an orderly manner,
for example sequentially from superior to inferior or
vice versa. Sections should include the endomyometrial
interface. The lower uterine segment should be sub-
mitted in toto with longitudinal sections including the
endocervical junction. Unremarkable ovaries and fallo-
pian tubes should be submitted in toto although there is
no evidence at the present time to support this practice.
Pathologists should be informed of a history of Lynch
syndrome to handle the specimen properly (40–42). The
demonstration of clinically occult endometrial carcino-
mas, some being microscopic, underscores the need for
in toto submission of the endometrium in the absence of
macroscopic lesions. Sections should include the endo-
myometrial interface, but the excess myometrium can be
trimmed (40,43). Unremarkable ovaries and fallopian
tubes should also be submitted in toto until enough
experience is accumulated to support or modify this
practice (40,43,44).
Women with Lynch syndrome are at increased risk of
malignancies, with colorectal, endometrial and ovarian
cancer being the most frequent (45–48). Endometrial
cancer is the most common extracolonic tumor in these
patients (47,49). Endometrial cancer cumulative incidence
at 70 years is consistently high for patients with MLH1
(34%), MSH2 (51%), MSH6 (49%), and PMS2 (24%)
germline mutations, and is frequently the ﬁrst malignancy
diagnosed in women with Lynch syndrome (50). Ovarian
cancer is the second most common extracolonic neoplasia
in women with Lynch syndrome with a cumulative
lifetime risk ranging from 6% to 14% (51–56). Prophy-
lactic hysterectomy and bilateral salpingo-oophorectomy
has been advocated as a cost-effective measure that
signiﬁcantly reduces the risk of gynecologic cancer in
Lynch syndrome patients. This procedure is currently
included in the National Comprehensive Cancer Network
(NCCN) guidelines for the management of patients with
Lynch syndrome who are either postmenopausal or who
have completed childbearing (41,57–61). The implemen-
tation of this procedure has been increasing progressively
(41,62). Endometrial ﬁndings in prophylactic hysterec-
tomy specimens in these patients include atypical hyper-
plasia and small and low grade endometrioid carcinomas
(40,43,44,63). The ﬁnding of small incidental endometrial
carcinomas in these specimens emphasizes the need to
submit the entire endometrium for microscopic examina-
tion (40,43,44,63). Regarding the need to submit in toto
unremarkable fallopian tubes and ovaries for microscopic
examination, using the SEE-FIM (Sectioning and Exten-
sively Examining the FIMbriated End) protocol, there is
no current evidence to support this practice (40,43,44,63);
however, as experience with these prophylactic specimens
is still limited, we recommend submitting unremarkable
adnexal structures entirely for microscopic examination as
it has been proposed by a group of investigators (43).
HOW MANY SECTIONS OF THE LOWER
UTERINE SEGMENT SHOULD BE TAKEN?
SHOULD THEY BE TAKEN HORIZONTALLY
OR VERTICALLY?
Recommendation
A minimum of 2 sections (1 anterior, 1 posterior)
should be submitted from the lower uterine segment.
Longitudinal sections are encouraged as they demon-
strate the relationship with the upper endocervix.
Most manuals reviewed advocate the use of
longitudinal sections of the lower uterine segment
(1 anterior/1 posterior) (6).
S16 A. MALPICA ET AL.
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SHOULD THE PARAMETRIAL
TISSUE/PARAMETRIUM BE SAMPLED
BEFORE OPENING THE UTERUS TO AVOID
CARRYOVER? HOW MUCH OF THE TISSUE
SHOULD BE SUBMITTED?
Recommendation
Parametrial tissue/parametrium should be
sampled before opening the uterus as this approach
minimizes the chance of ﬁnding carryovers. All of
the parametrial tissue/parametrium should be sub-
mitted for histologic examination. After inking the
parametrial margin, the parametrial tissue/parame-
trium should be blocked in sequential slices. If
macroscopic tumor is seen in the parametrial tissue/
parametrium, the most proximal parametrial section
should include the adjacent outer portion of the
cervical wall.
Very few of the manuals address this issue, and,
when mentioned, recommend removing the para-
metrial tissue/parametrium before opening the
uterus (6). Radical hysterectomies may be under-
taken in cases of endometrial cancer with an
epicenter in the lower uterine segment or with
prominent cervical involvement, and, as expected,
this type of specimen will contain parametrium. In
contrast, simple hysterectomies, which are the
specimens obtained for most endometrial carcino-
mas, do not usually contain parametrium; however,
a very small amount of parametrial tissue may
sometimes be included.
SHOULD THE CERVIX BE AMPUTATED OR
LEFT ATTACHED TO THE CORPUS?
Recommendation
The cervix should be left attached to the corpus
during the gross examination of a hysterectomy
specimen obtained for endometrial carcinoma.
No practice manual recommends amputation of
the cervix (6). Amputation could potentially inter-
fere in the pathologic assessment of the tumor and
the relationship with the upper endocervix, which
can be problematic even at the microscopic
level (64).
HOW MANY SECTIONS OF THE CERVIX
SHOULD BE TAKEN IF GROSSLY NORMAL?
Recommendation
At least 2 full thickness sections (1 anterior and 1
posterior) should be submitted from a grossly
unremarkable cervix. In cases of high-grade endome-
trial carcinoma or when the tumor is grossly close to
the cervix, submitting additional sections might be
considered. It is important to submit full thickness
sections of the uterine cervix because the presence of
tumor in the cervical stroma triggers measurement of
its depth of invasion in relation to the thickness of the
cervical wall.
All manuals reviewed except one advocate the
submission of 2 representative sections as indicated
above (6). The Royal College of Pathologists makes
a similar recommendation (28). One study found no
value in submitting more than the standard 2
sections of cervix (1 anterior and 1 posterior) in
hysterectomies for endometrial cancer without a
gross lesion in the cervix (65). However, a more
recent publication found that submitting the 2
standard sections of grossly unremarkable cervix
missed 24% of endometrial carcinomas involving the
cervix. Of note, in the latter publication, the patient
population was high-risk including patients with
serous carcinomas, FIGO grade 3 endometrioid
carcinomas, carcinosarcomas, and carcinomas with
lymphovascular invasion (66).
HOW MANY SECTIONS OF CERVIX SHOULD
BE TAKEN IF GROSSLY INVOLVED BY
ENDOMETRIAL CARCINOMA?
Recommendation
At least 2 representative sections of tumor involving
the cervix should be submitted. These sections must
include the full thickness of the cervical wall and the
ectocervical or vaginal cuff margin.
Documenting involvement of the cervical stroma
ensures accurate staging (FIGO stage II) (39). In
addition, providing the depth of cervical stromal
invasion in relation to the full thickness of the
cervical wall might be required for adjuvant therapy
purposes. The following guidelines are used by some
radiation oncology groups: (1) if <3 mm cervical
stromal invasion and no other feature suggesting the
need for additional adjuvant pelvic irradiation,
patients are treated with vaginal brachytherapy
only; (2) if invasion into the outer one-third of the
cervical stroma or invasion into the middle one-third
with vascular/lymphatic invasion, adjuvant pelvic
radiation is recommended; (3) if no evaluation of
lymph nodes was performed at time of surgery,
pelvic radiation is recommended for most patients
who have > 2 to 3 mm of cervical stromal invasion,
particularly if the tumor is high grade (12).
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HOW SHOULD A MORCELLATED
HYSTERECTOMY SPECIMEN THAT
CONTAINS AN UNEXPECTED ATYPICAL
ENDOMETRIAL HYPERPLASIA/ EIN OR
ENDOMETRIAL CARCINOMA BE HANDLED?
Recommendation
Gross examination of a morcellated hysterectomy
specimen requires special attention to identify any
endometrial abnormality, although this may be extreme-
ly difﬁcult to see in a morcellated specimen. If such an
abnormality is detected, the entire endometrial lesion and
the adjacent myometrium should be submitted for
microscopic examination. In addition, sampling of
myometrial tissue containing any serosal surface should
be undertaken. If the endometrium appears grossly
unremarkable and the initial representative sections
demonstrate the presence of atypical endometrial hyper-
plasia/EIN or endometrial carcinoma, careful regrossing
is required with the submission of all the visible
endometrial lining and adjacent myometrium. If the
morcellated specimen contains the uterine cervix, this
should be sampled representatively.
Unexpected endometrial cancer in morcellated
hysterectomy specimens obtained for presumptive benign
conditions is uncommon with a reported incidence
ranging from 0.07% to 3% (67–75). In general, it is
recommended that in such cases a preoperative endo-
metrial biopsy is performed to exclude such a possibility.
Although the use of endometrial dye instillation, either
trypan blue or methylene blue (76,77), has been proposed
as a useful technique to facilitate the identiﬁcation of the
endometrium in morcellated hysterectomies, this is not
commonly done. When an occult cancer is picked up in a
morcellated specimen, it may be very difﬁcult to assess
the depth of myoinvasion and thus accurate staging of
the endometrial cancer may not be possible (78).
HOW THOROUGHLY SHOULD THE
FALLOPIAN TUBES BE EXAMINED?
Recommendation
Gross examination of the fallopian tube must be
carefully undertaken and any areas with macroscopic
abnormalities should be submitted for microscopic
examination. If the fallopian tube is unremarkable, the
entire tube should be submitted for microscopic
examination using the SEE-FIM protocol. Should this
not be possible in all cases of endometrial cancer, the
SEE-FIM protocol should be used if uterine serous
carcinoma, clear cell carcinoma and carcinosarcoma
are present, while only the ﬁmbrial end should be
submitted in toto in other scenarios—using the guide-
lines of the SEE-FIM protocol, along representative
cross-sections of the remainder of the fallopian tube.
The SEE-FIM protocol encompasses the following
steps: (1) ﬁxing the specimen for several hours, (2)
amputating the distal 2 cm—the infundibulum and
ﬁmbrial end, and sectioning parallel to the long axis of
the fallopian tube, (3) taking cross sections at 2 to 3
mm intervals of the rest of the tube—the isthmus and
ampulla, (4) sectioning the ovary perpendicularly to
its long axis at 2 to 3 mm intervals and (5) to examine
one hematoxylin and eosin (H&E)-stained slide per
block (7) (Fig. 7). Although this system is being used
for all endometrial cancers at some institutions (79),
and its universal use in endometrial cancer is
advocated by some investigators (80,81), at this
point there is not enough evidence to support its
mandatory application regardless of histologic type
(82). Of note, it has been stated that expenses
secondary to complete processing are relatively
minor when balanced against potential expenses of a
recurrence (82). A practical alternative is to ensure
that at least the ﬁmbrial end of the fallopian tube, as
per the SEE-FIM protocol, is examined in addition to
the usual representative sections of the rest of the
fallopian tube (28,83).
FIG. 7. Sectioning and Extensively Examining the FIMbriated End
protocol, sectioning of adnexa to be submitted for microscopic
examination.
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HOW MUCH OF A NORMALLY SIZED AND
GROSSLY UNREMARKABLE OVARY SHOULD
BE SUBMITTED?
Recommendation
Gross examination of the ovary must be carefully
performed. If serous carcinoma, clear cell carcinoma or
carcinosarcoma, the entire ovary should be submitted
after slicing it perpendicularly to its long axis at 2 to 3
mm intervals. If possible, the same protocol should
be used for oophorectomy specimens accompanying
hysterectomies for other endometrial cancer histotypes.
Should the latter not be possible, at least 2 sections of
each ovary should be submitted.
Some investigators advocate the universal use of the
SEE-FIM protocol to handle grossly unremarkable
adnexa for endometrial cancer (79,81). Others proposed
that regardless of histotype, the ovaries should be
submitted in toto if they are small and unremarkable;
should they not be small, at least 2 sections should be
submitted (84). Of note, one study found that 2.7% of
grossly unremarkable ovaries removed as part of the
surgical treatment for endometrial cancer harbor micro-
scopic carcinoma (82).
HOW MANY SECTIONS OF OMENTUM
SHOULD BE EXAMINED HISTOLOGICALLY
WHEN REMOVED FOR STAGING PURPOSES
IN CASES OF SOME ENDOMETRIAL
CARCINOMA HISTOTYPES?
Recommendation
Omentectomy is part of the staging procedure of
endometrial serous carcinoma, clear cell carcinoma and
carcinosarcoma. The gross appearance and measurement
of the omentum should be provided. Omental tissue
should be sliced at 0.5 cm intervals to detect small
abnormalities. There are no standard sampling recom-
mendations, but in general the number of sections to be
submitted will depend on the gross examination ﬁndings.
If the omentum is grossly positive, one or 2 representative
sections are enough for microscopic evaluation, but if it is
grossly negative, one representative section per 2 or 3 cm
of maximal omental dimension (85) or at least a total of 4
blocks of tissue should be submitted (28).
Currently, guidelines on omental tissue sampling in
endometrial cancer are included in the Dataset for
Histological Reporting of Endometrial Cancer by the
Royal College of Pathologists (28), but not included in
the recommendations of either the CAP (11) or the
International Collaboration on Cancer Reporting (86)
The former recommends submission of a total of 4
blocks of tissue if grossly negative omentum. Others,
advocate for submission of one representative section
per 2 or 3 cm of maximal omental dimension if the
omentum is grossly unremarkable (73). One study
found that submitting 5 blocks of grossly negative
omentum has a sensitivity of 82% while examining 10
blocks raises the sensitivity to 95% (87).
HANDLING OF LYMPH NODES
Recommendations
Lymph nodes from different anatomical sites should
be sent in separate appropriately labelled specimen
containers and handled separately. They should be
carefully dissected from the adipose tissue. This can be
done with a thorough visual examination and palpation.
Clearing solutions are not routinely recommended as
they are not usually necessary. A small amount of
adipose tissue should be left around larger lymph nodes
to evaluate the presence or absence of extranodal
extension. Lymph nodes up to 2mm are embedded
whole. If larger than 2mm, they should be sliced in neat,
parallel slices at 2 to 3mm intervals—slicing should be
perpendicular to the long axis of the node. All grossly
unremarkable lymph node tissue should be submitted for
microscopic examination in properly identiﬁed cassettes.
The number of lymph nodes submitted per cassette and
the way they have been submitted, for example in toto—
if very small, or sectioned, should be speciﬁed in the
section code. With grossly positive lymph nodes,
representative sections to demonstrate the largest size
of tumor involvement as well as the surrounding adipose
tissue should be submitted for microscopic examination
and noted in the section code.
Nodal involvement is one of the most powerful
prognostic determinants in all cancers, and it predicts
distant recurrences in low-risk endometrial carcinoma
(88). At the same time systematic pelvic (+/− para-
aortic) nodal dissection, which is associated with
signiﬁcant morbidity, has demonstrated no survival
beneﬁt (89,90). and practices vary worldwide for this
reason. The proper retrieval of lymph nodes can be
achieved with a thorough examination by direct vision,
palpation, and sharp dissection and does not require the
use of clearing solutions (91). Slicing lymph nodes
perpendicular to their long axis at 2mm intervals
increases the chance of detecting metastases (92,93).
Submitting a rim of adipose tissue around the lymph
nodes allow the assessment of extracapsular extension
when there is tumor involvement. The latter ﬁnding has
been reported to be an important prognostic factor in
FIGO stage IIIC endometrial carcinoma by some
investigators (94).
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HANDLING OF SLNS
Recommendations
The description of the SLN should include measure-
ments, gross appearance, the presence of dye and the
radioactive tracer reading provided by the surgeon, if
any. The lymph node is sliced at 2.0 mm intervals
perpendicular to its long axis (Fig. 8). A small rim of
adipose tissue should be left around the lymph node.
The entire lymph node is submitted for microscopic
examination in properly identiﬁed cassettes. The SLN
is usually ultrastaged [i.e. additional recuts and/
or immunohistochemistry (IHC) for keratin], although
some institutions do not routinely undertake ultrastaging.
At the present time there is no universal ultrastaging
protocol; however, all institutions undertaking SLN
examination should have a standard procedure for SLNs
in endometrial cancer.
SLN removal has been introduced in the surgical
staging of endometrial carcinoma to decrease the
morbidity secondary to a lymphadenectomy but still
obtain information about the lymph node status (95).
The 2018 NCCNGuidelines indicate that SLN mapping
may be considered in patients with apparent uterine-
conﬁned endometrial cancer (clinical stage I disease) (57).
As delineated in the NCCN guidelines and the Society of
Gynecologic Oncology recommendations, there are
several key points when using this technique: (1) the
expertise of the surgeon and attention to technical detail
are critical to ensure mapping success; (2) superﬁcial and
deep cervical injection of dye has been validated as a
useful mapping technique; (3) complete evaluation of the
peritoneal cavity is mandatory; (4) SLN dissection starts
with the evaluation of the retroperitoneal spaces and
identiﬁcation of the sentinel drainage pathways that
emanate from the parametrial tissue, this is followed by
excision of all mapped SLNs; (5) any suspicious non-
SLN should be excised and frozen section may be
required to determine if a para-aortic lymphadenectomy
will be performed. Of note, routine frozen section of
SLNs is not advisable as small foci of tumor may be lost
when cutting the frozen section slides in addition to the
relatively low sensitivity for detection of metastases in
grossly unremarkable lymph nodes, (6) should mapping
failure occur in a hemi-pelvis, a side-speciﬁc lymphade-
nectomy should be performed; (7) pathology ultrastaging
is required to improve the detection of low-volume
metastases (57,95). The 2018 NCCN guidelines also state
that recent evidence indicates that SLN mapping may be
used in high-risk histologies (serous carcinoma, clear cell
carcinoma, and carcinosarcoma) (57). At the present
time, it has been established that the use of indocyanine
green, which requires use of a near infra-red camera for
localization, has similar rates of mapping success to those
of radiocolloid Tc-99 combined with blue dye (95). The
gross processing of SLNs is critical to ensure the success
of this technique. It is of utmost importance to obtain
serial perpendicular, thin (2.0mm) sections as an initial
step as this raises the odds of metastatic tumor detection
independent of the ultrastaging process (84). This
method not only facilitates the examination of the lymph
node subcapsular space and parenchymal surface, but is
designed to detect all metastases >2.0mm. A study
comparing 2 different ultrastaging protocols (method #1,
obtaining 5 H&E-stained levels at 250 μm with 2
unstained slides at each level—pankeratin IHC per-
formed on level 1 in cases with negative H&E or method
#2, 1 H&E level and 2 unstained slides cut at 250 μm
into the tissue block, pankeratin IHC performed in cases
with negative H&E) found no statistically signiﬁcant
differences between the methods with respect to number
of positive SLNs detected, size of metastasis or false-
negative rate (84).
There is no universal protocol for the ultrastaging
of SLNs (95). Protocols used at the 2 largest cancer
centers in the United Stated are as follows:
(1) The University of Texas M.D. Anderson Cancer
Center Protocol.
If the H&E-stained slide is negative for tumor, 3
consecutive sections at 250 µm into the parafﬁn block
are obtained (one for H&E and one of the remaining 2
to be used for keratin cocktail IHC if the additional
H&E-stained slide is negative (96) (Fig. 9A).
(1) Memorial Sloan Kettering Cancer Center Protocol.
FIG. 8. Sentinel lymph node, parallel slices are perpendicular to the
long axis of the specimen.
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If the initial H&E-stained slide is negative for
carcinoma and the endometrial cancer is myoinvasive
or associated with vascular/lymphatic invasion, 2 addi-
tional levels 50 µm apart are examined, at each level 2
slides are obtained, one for H&E and the second
for keratin cocktail IHC if the H&E-stained slide is
negative (97) (Fig. 9B).
REPORTING MARGINS OF HYSTERECTOMY
SPECIMENS FOR ENDOMETRIAL CANCER
Recommendations
The ectocervical margin of a hysterectomy specimen
should be reported in an endometrial cancer with
cervical involvement. The vaginal cuff and parametrial
margins should be reported in endometrial carcinomas
with cervical and/or parametrial involvement when a
radical hysterectomy is undertaken. Otherwise, reporting
of margins is optional (11). In cases where it is required
to report the above margins, including the distance
between the tumor and the margin is also optional (11).
Involvement of the uterine serosa by tumor should be
reported as this ﬁnding indicates FIGO stage III A
disease (39); however, the uterine serosa is not a margin
and should not be designated as such.
INTRAOPERATIVE ASSESSMENT
Recommendations
In cases where intraoperative assessment is requested
by the surgeon to determine whether staging will be
obtained, examine the specimen carefully, including the
uterine serosa, lower uterine segment, cervix and
adnexal structures. Identify the lesion, measure it,
cross-section the uterine wall, and evaluate the status
of the myometrium. Submit at least one section of the
lesion for frozen section including the adjacent uterine
wall. Should myometrial invasion be suspected, submit
the lesion and the full thickness of the uterine wall
containing the deepest point of myometrial invasion for
frozen section. Should cervical, uterine serosal or
adnexal involvement be suspected, submit appropriate
sections for frozen section examination.
Intraoperative evaluation of hysterectomy and
bilateral salpingo-oophorectomy specimens obtained
for endometrial cancer to determine parameters that
guide lymph nodes dissection, and in some cases
omentectomy, which are needed for staging and
prognosis, is commonly performed in the United
States, and much less frequently, if at all, in other
parts of the world (31). Histotype, tumor grade if
applicable, and depth of myometrial invasion are
typically reported (31). In addition, tumor size needs
to be determined if the Mayo algorithm is being
applied. Brieﬂy, using this algorithm cases are stratiﬁed
as low risk or high risk. Low risk is deﬁned as FIGO
grade 1 or 2 endometrioid carcinoma with myometrial
invasion ≤ 50% and primary tumor diameter ≤ 2 cm
while high risk is deﬁned as FIGO grade 3 endome-
trioid carcinoma, nonendometrioid histotype, myome-
trial invasion > 50% or primary tumor diameter > 2
cm. Cases in the low risk category are spared a
systematic pelvic and para-aortic lymphadenectomy
while these procedures are performed in cases in the
high risk category (21). Lower uterine segment,
cervical, and adnexal involvement and lymphovascular
space invasion should be reported if these ﬁndings are
identiﬁed during the intraoperative evaluation.
CONCLUSIONS
It is our hope that these ISGyP developed recom-
mendations will help to standardize the processing of
endometrial cancer specimens; this will facilitate accu-
rate pathologic reporting and a better understanding of
this disease which will be to the ultimate beneﬁt of
patients suffering from it.
FIG. 9. Ultrastaging protocols, MD Anderson Cancer Center (MDACC) (A) and Memorial Sloan Kettering Cancer Center (MSKCC),
ultrastaging will be obtained if there is myometrial or vascular/lymphatic invasion (*) (B). H&E indicates hematoxylin and eosin; IHC,
immunohistochemistry; SLN, sentinel lymph node.
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